Repligen (RGEN) Cash & Equivalents (2010 - 2026)

Repligen (RGEN) has 17 years of Cash & Equivalents data on file, last reported at $784.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $784.5 million, up 12.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $784.5 million (up 12.52% YoY), and the FY2025 annual result was $566.0 million, down 25.29% from the prior year.
• Cash & Equivalents grew to $784.5 million in Q1 2026 per RGEN's latest filing, from $566.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $809.1 million in Q2 2024 and troughed at $516.6 million in Q1 2023.
• A 5-year average of $671.6 million and a median of $697.2 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 51.1% in 2024, then decreased 25.29% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $523.5 million in 2022, then jumped by 43.53% to $751.3 million in 2023, then gained by 0.84% to $757.6 million in 2024, then declined by 25.29% to $566.0 million in 2025, then surged by 38.6% to $784.5 million in 2026.
• Business Quant data shows RGEN's Cash & Equivalents at $784.5 million in Q1 2026, $566.0 million in Q4 2025, and $748.7 million in Q3 2025.